-+ 0.00%
-+ 0.00%
-+ 0.00%

On December 22, Gilead's primary biliary cholangitis drug Seladelpar was approved in the Hainan Boao Lecheng International Medical Tourism Pilot Zone. It is suitable for treating adult PBC patients with poor response to UDCA alone in combination with ursodeoxycholic acid, or as a single agent to treat adult PBC patients who are intolerant to UDCA.

Zhitongcaijing·12/23/2025 02:49:04
Listen to the news
On December 22, Gilead's primary biliary cholangitis drug Seladelpar was approved in the Hainan Boao Lecheng International Medical Tourism Pilot Zone. It is suitable for treating adult PBC patients with poor response to UDCA alone in combination with ursodeoxycholic acid, or as a single agent to treat adult PBC patients who are intolerant to UDCA.